The Cancer Proteomics Core pushes the limits of proteomics and metabolomics technologies and specializes in cancer projects utilizing blood, urine, cerebrospinal fluid, saliva, cyst fluids, interstitial fluids, cell and tissue extracts to: gain insight into cancer processes;discover new biomarkers for early detection, diagnosis, prognosis and outcome prediction;study population effects;manage clinical trials;evaluate drug efficacy and toxicity;stratify patients;identify tumor antigens;and accelerate drug development. A unique aspect of the CPC has been its expertise in basic, translational and clinical cancer research, as well as in proteomics, metabolomics, systems biology, and bioinformatics. Unlike other proteomics facilities, the staff is able to provide expertise in all aspects of cancer research, as well as study design and data analysis and understands the complexities and challenges of proteomics projects. The Core was first approved as an Established Shared Resource in the CCSG renewal application. It has been directed by Towia Libermann, PhD, since its founding in 2004. This facility has grown considerably during the project period, with a steady increase in usage. Director: Towia Libermann, PhD(BIDMC) Category: 1.36 (Proteomics) Management: Joint (Cancer Center and Institutional)

Public Health Relevance

The Core provides investigators involved in clinical and translational studies with access to comprehensive high sensitivity, high resolution and high throughput proteomics and metabolomics services. There is particular emphasis on clinical sample analysis and in-depth scientific consultation in proteomics, metabolomics and data analysis. Basic researchers who are exploring signaling pathways and other aspects of cancer biology are also able to receive access to sophisticated proteomic and metabolomic services and expert consultation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-48
Application #
8469423
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
48
Fiscal Year
2013
Total Cost
$255,155
Indirect Cost
$63,430
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Lin, Ruei-Zeng; Lee, Chin Nien; Moreno-Luna, Rafael et al. (2017) Host non-inflammatory neutrophils mediate the engraftment of bioengineered vascular networks. Nat Biomed Eng 1:
Wang, Meng; Han, Jing; Marcar, Lynnette et al. (2017) Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res 77:2018-2028
Ignatius, Myron S; Hayes, Madeline N; Lobbardi, Riadh et al. (2017) The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Rep 19:2304-2318
Nugent, Alicia A; Park, Jong G; Wei, Yan et al. (2017) Mutant ?2-chimaerin signals via bidirectional ephrin pathways in Duane retraction syndrome. J Clin Invest 127:1664-1682
Breitkopf, Susanne B; Taveira, Mateus De Oliveira; Yuan, Min et al. (2017) Serial-omics of P53-/-, Brca1-/- Mouse Breast Tumor and Normal Mammary Gland. Sci Rep 7:14503
Bowden, John A; Heckert, Alan; Ulmer, Candice Z et al. (2017) Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human Plasma. J Lipid Res 58:2275-2288
Lindsley, R Coleman; Saber, Wael; Mar, Brenton G et al. (2017) Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med 376:536-547
Mita, Monica M; Mita, Alain C; Moseley, Jennifer L et al. (2017) Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. Br J Cancer 117:1258-1268
Hu, Yuebi; Alden, Ryan S; Odegaard, Justin I et al. (2017) Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clin Cancer Res 23:7351-7359
Lam, Hilaire C; Liu, Heng-Jia; Baglini, Christian V et al. (2017) Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. Oncotarget 8:64714-64727

Showing the most recent 10 out of 371 publications